SG11201401215VA - New therapy for transthyretin-associated amyloidosis - Google Patents
New therapy for transthyretin-associated amyloidosisInfo
- Publication number
- SG11201401215VA SG11201401215VA SG11201401215VA SG11201401215VA SG11201401215VA SG 11201401215V A SG11201401215V A SG 11201401215VA SG 11201401215V A SG11201401215V A SG 11201401215VA SG 11201401215V A SG11201401215V A SG 11201401215VA SG 11201401215V A SG11201401215V A SG 11201401215VA
- Authority
- SG
- Singapore
- Prior art keywords
- transthyretin
- new therapy
- associated amyloidosis
- amyloidosis
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11382326 | 2011-10-24 | ||
| PCT/EP2012/070945 WO2013060668A1 (en) | 2011-10-24 | 2012-10-23 | New therapy for transthyretin-associated amyloidosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201401215VA true SG11201401215VA (en) | 2014-08-28 |
Family
ID=47076222
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201401215VA SG11201401215VA (en) | 2011-10-24 | 2012-10-23 | New therapy for transthyretin-associated amyloidosis |
| SG10201609933WA SG10201609933WA (en) | 2011-10-24 | 2012-10-23 | New therapy for transthyretin-associated amyloidosis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201609933WA SG10201609933WA (en) | 2011-10-24 | 2012-10-23 | New therapy for transthyretin-associated amyloidosis |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US9610270B2 (https=) |
| EP (1) | EP2770988B1 (https=) |
| JP (1) | JP6068484B2 (https=) |
| KR (1) | KR102017354B1 (https=) |
| CN (1) | CN103889407B (https=) |
| AU (2) | AU2012327275B2 (https=) |
| BR (1) | BR112014009322B1 (https=) |
| CA (1) | CA2852808C (https=) |
| CL (1) | CL2014000893A1 (https=) |
| CY (1) | CY1118151T1 (https=) |
| ES (1) | ES2593038T3 (https=) |
| IL (1) | IL231907B (https=) |
| MX (2) | MX347784B (https=) |
| PL (1) | PL2770988T3 (https=) |
| PT (1) | PT2770988T (https=) |
| RU (2) | RU2747536C2 (https=) |
| SG (2) | SG11201401215VA (https=) |
| WO (1) | WO2013060668A1 (https=) |
| ZA (1) | ZA201402546B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2747536C2 (ru) * | 2011-10-24 | 2021-05-06 | Сом Инновэйшн Биотек, С.Л. | Новая терапия транстиретин-ассоциированного амилоидоза |
| CN113599539A (zh) * | 2014-08-29 | 2021-11-05 | 阿尔尼拉姆医药品有限公司 | 治疗甲状腺素运载蛋白（ttr）介导的淀粉样变性的方法 |
| EP3275433A1 (en) * | 2016-07-29 | 2018-01-31 | Som Innovation Biotech S.L. | Sustained release composition comprising micronized tolcapone |
| AU2019236469A1 (en) * | 2018-03-12 | 2020-10-08 | Corino Therapeutics, Inc. | Combination therapy for TTR amyloidosis |
| CA3141998A1 (en) * | 2019-05-31 | 2020-12-03 | Plex Pharmaceuticals, Inc. | Pharmacological agents for treating protein aggregation diseases of the eye |
| EP4243798A4 (en) * | 2020-11-13 | 2024-08-21 | Plex Pharmaceuticals, Inc. | PHARMACOLOGICAL AGENTS FOR TREATING OCULAR PATHOLOGIES |
| CN114324693B (zh) * | 2022-01-14 | 2023-01-13 | 大连博源医学科技有限公司 | 一种血液中转甲状腺素蛋白(ttr)四聚体浓度测定的预处理方法和检测方法 |
| JP2025536853A (ja) * | 2022-10-10 | 2025-11-07 | コリノ セラピューティクス，インク． | 放出調節トルカポン処方剤 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744368A (en) | 1993-11-04 | 1998-04-28 | Research Foundation Of State University Of New York | Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR) |
| AU5727798A (en) | 1996-12-23 | 1998-07-17 | Texas A & M University, The | Anti-amyloidogenic agents |
| FI20002044A0 (fi) * | 2000-09-15 | 2000-09-15 | Orion Yhtymae Oyj | Comt-entsyymiä estäviä naftaleenijohdannaisia |
| EP1372682B1 (en) | 2001-03-15 | 2012-05-02 | Proteotech Inc. | Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic aa amyloidosis, and other amyloid disorders |
| WO2003063880A1 (en) | 2002-01-29 | 2003-08-07 | Protemix Corporation Limited | Disruption of islet amyloid by polycyclic compounds |
| US20040175382A1 (en) | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
| KR20060124712A (ko) | 2004-02-20 | 2006-12-05 | 노파르티스 아게 | 신경퇴행 및 인지 장애를 치료하기 위한 ｄｐｐ ⅳ 억제제 |
| CN1921856A (zh) * | 2004-02-20 | 2007-02-28 | 诺瓦提斯公司 | 用于治疗神经变性疾病和认知障碍的dpp－iv抑制剂 |
| WO2005113523A1 (en) | 2004-05-20 | 2005-12-01 | Foldrx Pharmaceuticals, Inc. | 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| DE602005019582D1 (de) | 2004-08-30 | 2010-04-08 | Seo Hong Yoo | Nervenschutzwirkung von aufgelöster udca bei einem fokalen ischämischen modell |
| GB2429645A (en) | 2006-03-10 | 2007-03-07 | Sekhsaria Chemicals Ltd | Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent |
| US20120016037A1 (en) | 2006-07-24 | 2012-01-19 | Frank Toppo | Method for prevention and treatment of Alzheimers |
| GB0718718D0 (en) | 2007-09-25 | 2007-11-07 | Pentraxin Therapeutics Ltd | Compound and use thereof |
| DE102010010572A1 (de) | 2010-03-08 | 2011-09-08 | Mahle International Gmbh | Trockenseparator |
| RU2747536C2 (ru) * | 2011-10-24 | 2021-05-06 | Сом Инновэйшн Биотек, С.Л. | Новая терапия транстиретин-ассоциированного амилоидоза |
-
2012
- 2012-10-23 RU RU2017119539A patent/RU2747536C2/ru active
- 2012-10-23 MX MX2014004863A patent/MX347784B/es active IP Right Grant
- 2012-10-23 BR BR112014009322-9A patent/BR112014009322B1/pt active IP Right Grant
- 2012-10-23 PL PL12778323T patent/PL2770988T3/pl unknown
- 2012-10-23 CN CN201280051812.8A patent/CN103889407B/zh not_active Expired - Fee Related
- 2012-10-23 SG SG11201401215VA patent/SG11201401215VA/en unknown
- 2012-10-23 ES ES12778323.1T patent/ES2593038T3/es active Active
- 2012-10-23 JP JP2014536290A patent/JP6068484B2/ja active Active
- 2012-10-23 CA CA2852808A patent/CA2852808C/en active Active
- 2012-10-23 SG SG10201609933WA patent/SG10201609933WA/en unknown
- 2012-10-23 KR KR1020147010767A patent/KR102017354B1/ko active Active
- 2012-10-23 US US14/353,459 patent/US9610270B2/en active Active
- 2012-10-23 AU AU2012327275A patent/AU2012327275B2/en not_active Ceased
- 2012-10-23 EP EP12778323.1A patent/EP2770988B1/en active Active
- 2012-10-23 WO PCT/EP2012/070945 patent/WO2013060668A1/en not_active Ceased
- 2012-10-23 PT PT127783231T patent/PT2770988T/pt unknown
- 2012-10-23 MX MX2017006182A patent/MX385516B/es unknown
- 2012-10-23 RU RU2014114930A patent/RU2623062C2/ru active
-
2014
- 2014-04-03 IL IL231907A patent/IL231907B/en active IP Right Grant
- 2014-04-08 ZA ZA2014/02546A patent/ZA201402546B/en unknown
- 2014-04-09 CL CL2014000893A patent/CL2014000893A1/es unknown
-
2016
- 2016-09-20 CY CY20161100934T patent/CY1118151T1/el unknown
-
2017
- 2017-03-02 US US15/448,054 patent/US10045956B2/en active Active
- 2017-04-21 AU AU2017202670A patent/AU2017202670B2/en not_active Ceased
-
2018
- 2018-08-13 US US16/101,882 patent/US10449169B2/en active Active
-
2019
- 2019-09-12 US US16/569,055 patent/US10786473B2/en active Active
-
2020
- 2020-08-28 US US17/005,893 patent/US11564899B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201305897B (en) | Combination therapy | |
| PT2710018T (pt) | Compostos macrocíclicos como inibidores de proteína quinases | |
| GB201118652D0 (en) | New compounds | |
| GB201118654D0 (en) | New compounds | |
| LT2776436T (lt) | Naujieji junginiai | |
| GB201106803D0 (en) | Sonodynamic therapy | |
| ZA201400120B (en) | Combination therapy | |
| GB201114212D0 (en) | Therapeutic agents | |
| GB201119401D0 (en) | Therapeutic agents | |
| GB201106814D0 (en) | New compounds | |
| ZA201402546B (en) | New therapy for transthyretin-associated amyloidosis | |
| PT3034071T (pt) | Nova associação | |
| ZA201400236B (en) | Combination als therapy | |
| PL2723330T3 (pl) | Lek kombinowany zawierający środek naczynioskurczowy | |
| EP2771012A4 (en) | NEW CONNECTIONS | |
| ZA201502595B (en) | Therapeutic methods | |
| EP2701744A4 (en) | COMBINATION THERAPY | |
| PH12014501058A1 (en) | Therapeutic agent for arthrosis | |
| GB201206306D0 (en) | Therapeutic apparatus | |
| GB201102913D0 (en) | Novel therapeutic | |
| GB201102289D0 (en) | New use | |
| GB201114226D0 (en) | Combination therapy | |
| GB201120096D0 (en) | Novel therapy | |
| GB201110895D0 (en) | Therapeutic use | |
| GB201110614D0 (en) | Therapeutic agents |